FIRST AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
This First Amendment to Collaboration, Option and License Agreement (this “First Amendment”), dated August 13, 2019 (the “First Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
FOURTH Amendment to collaboration AND LICENSE AGREEMENTCollaboration and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • New York
This Fourth Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of August 11, 2022 (the “Amendment Date”) by and between Genzyme Corporation, a Massachusetts corporation (“Sanofi”), and Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”). Sanofi and Nurix are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”
SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
This Second Amendment to Collaboration, Option and License Agreement (this “Second Amendment”), dated September 9, 2022 (the “Second Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
THIRD Amendment to collaboration AND LICENSE AGREEMENTCollaboration and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • New York
This Third Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of July 7, 2022 (the “Amendment Date”) by and between Genzyme Corporation, a Massachusetts corporation (“Sanofi”), and Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”). Sanofi and Nurix are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”
SEcond Amendment to collaboration AND LICENSE AGREEMENTCollaboration and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • New York
This Second Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of December 16, 2021 (the “Amendment Date”) by and between Genzyme Corporation, a Massachusetts corporation (“Sanofi”), and Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”). Sanofi and Nurix are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties.”
